|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
35
|
|
pubmed:dateCreated |
2009-12-9
|
|
pubmed:abstractText |
The occurrence of KRAS mutation is predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to patients with wild-type KRAS tumors. However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/BRAF protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/EGFR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins B-raf,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BachetJean-BaptisteJB,
pubmed-author:BibeauFrédericF,
pubmed-author:BoigeValérieV,
pubmed-author:BouchéOlivierO,
pubmed-author:BucEmmanuelE,
pubmed-author:CayreAnneA,
pubmed-author:DucreuxMichelM,
pubmed-author:LandiBrunoB,
pubmed-author:Laurent-PuigPierreP,
pubmed-author:LecomteThierryT,
pubmed-author:LievreAstridA,
pubmed-author:ManceauGillesG,
pubmed-author:Penault-LlorcaFrédériqueF,
pubmed-author:ReidJuliaJ,
pubmed-author:RougierPhilippeP,
pubmed-author:StoneStevenS,
pubmed-author:YchouMarcM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5924-30
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19884556-Antibodies, Monoclonal,
pubmed-meshheading:19884556-Antineoplastic Agents,
pubmed-meshheading:19884556-Colorectal Neoplasms,
pubmed-meshheading:19884556-Disease-Free Survival,
pubmed-meshheading:19884556-France,
pubmed-meshheading:19884556-Gene Amplification,
pubmed-meshheading:19884556-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19884556-Humans,
pubmed-meshheading:19884556-Immunohistochemistry,
pubmed-meshheading:19884556-In Situ Hybridization,
pubmed-meshheading:19884556-In Situ Hybridization, Fluorescence,
pubmed-meshheading:19884556-Individualized Medicine,
pubmed-meshheading:19884556-Kaplan-Meier Estimate,
pubmed-meshheading:19884556-Mutation,
pubmed-meshheading:19884556-PTEN Phosphohydrolase,
pubmed-meshheading:19884556-Patient Selection,
pubmed-meshheading:19884556-Predictive Value of Tests,
pubmed-meshheading:19884556-Proportional Hazards Models,
pubmed-meshheading:19884556-Proto-Oncogene Proteins,
pubmed-meshheading:19884556-Proto-Oncogene Proteins B-raf,
pubmed-meshheading:19884556-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19884556-Retrospective Studies,
pubmed-meshheading:19884556-Risk Assessment,
pubmed-meshheading:19884556-Time Factors,
pubmed-meshheading:19884556-Treatment Outcome,
pubmed-meshheading:19884556-Tumor Markers, Biological,
pubmed-meshheading:19884556-ras Proteins
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
|
|
pubmed:affiliation |
INSERM UMR-S775 Molecular Basis of Xenobiotics Response, Paris, France. pierre.laurent-puig@parisdescartes.fr
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
